The role of ets factors in tumor angiogenesis.
Angiogenesis is a critical component of tumor growth. A number of growth factors, including VEGF, FGF, and HGF, have been implicated as angiogenic growth factors that promote tumor angiogenesis in different types of cancer. Ets-1 is the prototypic member of the Ets transcription factor family. Ets-1 is known to be a downstream mediator of angiogenic growth factors. Expression of Ets-1 in a variety of different tumors is associated with increased angiogenesis. A role for other selected members of the Ets transcription factor family has also been shown to be important for the development of tumor angiogenesis. Because Ets factors also express a number of other important genes involved in cell growth, they contribute not only to tumor growth, but to disease progression. Targeting Ets factors in mouse tumor models through the use of dominant-negative Ets proteins or membrane permeable peptides directed at competitively inhibiting the DNA binding domain has now demonstrated the therapeutic potential of inhibiting selected Ets transcription factors to limit tumor growth and disease progression.
Oettgen
Peter
P
Division of Cardiology, and Molecular and Vascular Biology, Department of Medicine, Research North RM 270D, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA.
Blood. 2009 Jul 30;114(5):934-5
19643995
J Biol Chem. 1995 Oct 13;270(41):24258-63
7592633
Oncogene. 2008 Jun 12;27(26):3662-72
18212735
J Virol. 2007 Apr;81(8):3980-91
17287278
Genes Dev. 1998 May 1;12(9):1315-26
9573048
Blood. 2009 Jul 30;114(5):1123-30
19411629
Mol Cell Biol. 2003 Dec;23(23):8614-25
14612405
J Cancer Res Clin Oncol. 2003 Jul;129(7):430-6
12851814
J Clin Invest. 2005 Sep;115(9):2508-16
16138193
Verh Dtsch Ges Pathol. 1999;83:212-5
10714212
Cancer Sci. 2003 Sep;94(9):769-73
12967474
Oncogene. 2002 Dec 5;21(55):8506-9
12466970
Hum Pathol. 2009 Apr;40(4):588-93
18992913
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9184-9
9689055
Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1803-9
15284088
Blood. 1998 Feb 15;91(4):1399-406
9454771
Cancer Lett. 2000 Nov 10;160(1):45-50
11098083
J Biomed Sci. 2003 May-Jun;10(3):320-7
12711859
Circulation. 2004 Jun 22;109(24):3035-41
15173033
Ann Oncol. 2002 Oct;13(10):1605-11
12377649
Lab Invest. 1999 Apr;79(4):407-16
10211993
Biochem Biophys Res Commun. 2001 Nov 23;289(1):39-43
11708773
Mod Pathol. 1999 Jun;12(6):618-26
10392639
Circ Res. 1999 May 28;84(10):1177-85
10347092
Nucleic Acids Res. 2003 Dec 1;31(23):e152
14627842
Nature. 2009 Oct 22;461(7267):1084-91
19847259
Int Surg. 2003 Jan-Mar;88(1):25-33
12731728
Zhonghua Bing Li Xue Za Zhi. 2002 Jun;31(3):222-6
12475439
Immunity. 1998 Oct;9(4):555-63
9806641
Eur J Biochem. 1993 Jan 15;211(1-2):7-18
8425553
J Biol Chem. 2006 Sep 1;281(35):25259-69
16829517
Cancer Gene Ther. 2009 Feb;16(2):137-48
18772901
FASEB J. 1999 Feb;13(2):377-86
9973326
J Biol Chem. 2003 Dec 5;278(49):49358-68
14507917
Ann Oncol. 2002 Oct;13(10):1598-604
12377648
Cancer Res. 1997 May 15;57(10):2013-9
9157999
Br J Haematol. 2008 Dec;143(5):622-31
19036013
Cancer Res. 2008 Jun 15;68(12):4649-57
18559510
Oncology. 2004;66(5):420-8
15331930
Oncogene. 2003 Mar 27;22(12):1795-806
12660815
J Biol Chem. 2003 Feb 28;278(9):7520-30
12464608
J Immunol. 2006 Aug 15;177(4):2651-61
16888027
Neoplasia. 2007 Mar;9(3):184-91
17401458
Blood. 2006 Apr 15;107(8):3153-60
16352813
Mol Cell. 2001 Dec;8(6):1267-76
11779502
Mech Dev. 2000 Feb;90(2):237-52
10640707
Oncogene. 2006 Nov 2;25(52):6959-67
16715134
Circ Res. 2001 Feb 2;88(2):237-44
11157678
Curr Drug Targets. 2007 Feb;8(2):257-68
17305503
J Immunol. 1998 Dec 1;161(11):6084-92
9834092